Inventiva SA (IVA)
2.97
-0.19
(-6.01%)
USD |
NASDAQ |
Jun 14, 16:00
2.97
0.00 (0.00%)
After-Hours: 20:00
Inventiva Total Liabilities (Quarterly): 112.30M for Dec. 31, 2023
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 112.30M |
| June 30, 2023 | 85.29M |
| June 30, 2023 | 85.29M |
| December 31, 2022 | 75.63M |
| June 30, 2022 | 40.39M |
| June 30, 2022 | 40.39M |
| June 30, 2021 | 34.14M |
| March 31, 2021 | 35.13M |
| June 30, 2020 | 30.36M |
| December 31, 2019 | 17.44M |
| Date | Value |
|---|---|
| June 30, 2019 | 22.09M |
| June 30, 2019 | 22.09M |
| December 31, 2018 | 20.84M |
| June 30, 2018 | 20.12M |
| June 30, 2018 | 20.12M |
| December 31, 2017 | 14.96M |
| June 30, 2017 | 11.91M |
| June 30, 2017 | 11.91M |
| December 31, 2016 | 14.30M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
17.44M
Minimum
Dec 2019
112.30M
Maximum
Dec 2023
50.05M
Average
37.76M
Median
Total Liabilities (Quarterly) Benchmarks
| DBV Technologies SA | 34.24M |
| Cellectis SA | 263.89M |
| Genfit SA | 117.09M |
| Innate Pharma SA | 146.24M |
| Nanobiotix SA | 105.83M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 76.89M |
| Shareholders Equity (Quarterly) | -35.41M |
| Debt to Equity Ratio | -0.9654 |
| Current Ratio | 0.9607 |
| Net Debt Paydown Yield | -2.57% |